Activation of the serine/threonine kinase, protein kinase D (PKD/PKCµ) via a phorbol ester/PKC-dependent pathway involves phosphorylation events. The present study identifies five in vivo phosphorylation sites by mass spectrometry, and the role of four of them was investigated by site-directed mutagenesis. Four sites are autophosphorylation sites, the first of which (Ser-916) is located in the carboxyl terminus: its phosphorylation modifies the conformation of the kinase and influences duration of kinase activation, but is not required for phorbol ester-mediated activation of PKD. The second autophosphorylation site (Ser-203) lies in that region of the regulatory domain, which in PKCµ interacts with 14-3-3τ. The last two autophosphorylation sites (Ser-744 and Ser-748) are located in the activation loop, but are only phosphorylated in the isolated PKD-catalytic domain and not in the full-length PKD; they may affect enzyme catalysis, but are not involved in the activation of wild-type PKD by phorbol ester. We also present evidence for proteolytic activation of PKD. The fifth site (Ser-255) is transphosphorylated downstream of a PKC-dependent pathway after in vivo stimulation with phorbol ester. In vivo phorbol ester stimulation of an S255E mutant no longer requires PKC-mediated events. In conclusion, our results show that PKD is a multisite phosphorylated enzyme, and suggest that its phosphorylation may be an intricate process which regulates its biological functions in very distinct ways.
INTRODUCTION
Protein kinase D (PKD) is a serine/threonine protein kinase, also called PKCµ, that was first described as a member of the novel protein kinase C (PKC) subgroup (δ, ε, η and θ) (1, 2) . PKD contains two cysteine-rich domains that bind diacylglycerol (DAG) or phorbol ester, but it lacks the calcium binding domain seen in the classical PKCs. However, PKD also contains a pleckstrin homology domain that regulates its kinase activity (3), but does not harbor the typical PKC autoinhibitory pseudosubstrate motif. Moreover, the PKD catalytic domain is only distantly related to the kinase subdomains of the PKC family, but shows homology to that of the Ca 2+ -regulated kinases, such as myosin light chain kinase and calcium/calmodulin kinase I. Finally, the substrate specificity of PKD is probably different from that of other PKCs, since it is specific for a unique peptide sequence (4) . These characteristics have rendered it difficult to classify PKD in the scheme of protein kinases (5) and PKD might be the first member of a new protein kinase family and/or subgroup.
Regulation of protein kinases is achieved through a variety of mechanisms that include auto-and transphosphorylation 1 events and control by regulatory domains or subunits.
Mutagenesis studies have highlighted the regulatory domain of PKD/PKCµ in the negative control of its activity (3, 6) . Despite the fact that most protein kinases share a largely conserved catalytic domain structure, their regulation by phosphorylation is very diverse (7, 8) . Phosphorylation of specific threonine, serine or tyrosine residues can occur at a number of sites, some of which are located at the N-terminal or C-terminal ends of the enzyme (e.g. in calmodulin-dependent kinase II and PKCβII) or on other subunits (e.g. on phosphorylase kinase). A key feature for regulation is the phosphorylation of residues in the so-called kinase "activation loop" located between subdomains VII and VIII of the kinase core. Here again, this general mechanism holds for most, but not for all protein kinases. Phosphorylation of residue(s) in the activation loop may be due to autophosphorylation (e.g. cAPK 2 , c-Src and IRK) or transphosphorylation catalyzed by another protein kinase (e.g. PKBα, p70 S6K kinase (probably PDK-1), which phosphorylates Thr-500 in the activation loop thereby leading to kinase activation and autophosphorylation of two other sites in the C-terminus (9) . PKD/PKCµ has been shown to be activated by pharmalogical agents such as phorbol ester and bryostatin 1 (10, 11, 12) and by physiological stimuli such as platelet-derived growth factor (PDGF), tumor-necrosis-factor (TNF), angiotensin II and neuropeptide agonists (13, 14, 15, 16) . Recent data have shown that PKD plays a role in the regulation of Golgi structure and function (17) . Interestingly, PKD may also serve as a molecular switch to promote cell proliferation, while inhibiting apoptosis (16, 18, 19) . PKD activation was first described as a phorbol ester or diacylglycerol/phospholipid-dependent process. In vitro and in vivo experiments have shown that immunopurified PKD is markedly stimulated by either biologically active phorbol ester or diacylglycerol, in the presence of phosphatidylserine (10, 11, 20) . More recently, attention was focussed on phosphorylation events that control the PKD activity (21) . These observations were based on the fact that PKD activation was maintained during cell disruption and immunoprecipiation. Additional data, including the use of PKC inhibitors and cotransfection of PKD with constitutively active mutants of PKCε and PKCη, indicated that PKD was activated by phosphorylation in vivo through a PKC-dependent signal transduction pathway (11, 12, 13) . Recent results have demonstrated that PKCη interacts with the PH domain of PKD, suggesting a direct link between PKCη and PKD (22) .
Little is known about how phosphorylation regulates PKD activity, and the phosphorylation sites that mediate its biological functions have not been identified. The group of Rozengurt proposed that the in vivo activation of PKD by phorbol ester results from the phosphorylation of two activation loop serine residues, namely Ser-744 and Ser-748, via a novel PKC-dependent signal transduction pathway (23) . However, no sequence studies were undertaken to unambiguously determine that these two serines were actually being phosphorylated in vivo. The C-terminal Ser-916 was suggested to be autophosphorylated in PKCµ/PKD, as it was recognized by a phosphospecific peptide antibody (24 
Site-directed mutagenesis, expression and purification
The phagemid, called pBluescript (SK)II+/PKD (pBS/PKD), containing the full-length PKD cDNA (10) , was used as a template to create eight single mutations (S916A, S916E, S744A, S748A, S744E, S748E, S255A and S255E) using the Quickchange kit (Stratagene) following instructions provided by the manufacturer. The different mutations were verified by restriction analysis and DNA sequencing. A kinase-dead mutant of PKD (K628N) was also generated by the same strategy.
The DNA sequence encoding wild-type or mutated PKD was subcloned into the eukaryotic expression vector pGMEX-T3 that has been used to overexpress Gluthatione Stransferase (GST)-fusion proteins in eukaryotic cells under an EF1a promoter. The pBS/PKD phagemids were cleaved with Not I to release the cDNA for PKD, which was then inserted into the compatible ends of pGMEX-T3 to create pGMEX-T3-PKD. To overexpress untagged-PKD constructs, wild-type and mutant proteins were also cloned in pcDNA3 vector as described (10) To prepare the PKD catalytic domain fusion protein (GST-catPKD), a 1014-base pair fragment comprising the entire catalytic domain of PKD was generated by PCR and inserted into pBluescript (SK)II+. The assembled fragment was then subcloned into pGMEXT-3 between the SalI and NotI restriction sites.
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To prepare purified GST-PKD or GST-catPKD, 10 cm diameter dishes of human embryonic kidney 293 T cells (HEK 293T), expressing the SV40 large T antigen, were cultured and each dish transfected with 7 µg of pGMEX-T3-PKD plasmid DNA using the modified calcium phosphate method (25) . Briefly, 2×10 6 HEK 293T cells per dish were grown for 24 hours before transfection at 37°C and 5% CO 2 in DMEM supplemented with 10% (v/v) fetal bovine serum, 100 units/ml penicillin and 100 µg/ml streptomycin. The DNA was mixed with equal volumes of 0.25M CaCl 2 and BES-buffered solution and incubated for 30 min at room temperature. The calcium phosphate-DNA solution was added onto mediumcontaining plates and incubated for 16 hours at 37°C, 3% CO 2 . The medium was then replaced with fresh DMEM containing 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin. The cells were used for experimental purposes 48 hours later. Phorbol ester treatment was with 1µM PDBu for 15 min. The cells were then washed once with icecold PBS and each dish lysed in 1 ml of ice-cold buffer A, pH 7.5 ( 50 mM Tris, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , 50 mM NaF, 5 mM NaPPi, 0.2 µM microcystin, 0.27 M sucrose, 1 mM AEBSF, 1 µg/ml Leupeptin, 15 mM β-mercaptoethanol, 1% (v/v) Triton X-100). Lysates were briefly vortexed and centrifuged at 10000 g for 15 min. The supernatants were pooled and incubated for 1 hour at 4°C on a rotating platform with 25 µl (gel bed vol.) per dish of Glutathione-Sepharose previously equilibrated in one bed volume of Buffer A. The suspension was centrifuged for 10 min at 3000 g and the beads were washed once with 10 bed vol. of Buffer A containing 0.5 M NaCl and once with 10 bed vol. of Buffer B, pH 8.0 (50 mM Tris, 0.1 mM EGTA, 0.27 M sucrose, 15 mM β-mercaptoethanol, 10 % glycerol (v/v), 50 mM NaCl). GST-PKD was eluted from the gel with 2 times one bed volume of Buffer B containing 20 mM reduced glutathione. The combined eluates were divided into aliquots and stored at -80°C.
PKD kinase assay and immunoprecipitation
PKD activity was measured with syntide-2 peptide as substrate (1) under the conditions described in the legends to the figures and tables. One Unit of PKD activity corresponds to the amount of enzyme catalysing the formation of 1 nmol of product per min under the assay conditions. Immunoprecipitation of PKD from cell lysates with a polyclonal antibody and kinase assay was as described (15) .
In vitro autophosphorylation assay
Purified GST-PKD (30 µg) was incubated in buffer containing 15 mM Tris, pH 8.0, 5 mM MgCl 2 and 0.1 mM [γ- 
In vivo labeling
HEK 293T cells were cultured and transfected as described above. The dishes were washed 5 times with phosphate free DMEM containing 100 units/ml penicillin and 100 µg/ml streptomycin and labeled for 4 hours with 3 ml per dish of phosphate free DMEM containing 150 µCi/ml of 32 P orthophosphate. Cells were stimulated with PBDu and the PKD-GST proteins purified as described above.
Identification of Phosphorylation sites by Electrospray Ionization-tandem Mass

Spectrometry (ESI-MS/MS)
To identify autophosphorylation sites, GST-PKD (50 µg) was incubated at 30°C, with 0.1 mM [γ- 
Identification of Phosphorylation sites by High Performance Liquid ChromatographyElectrospray Ionization-tandem Mass Spectrometry (HPLC-ESI-MS/MS)
To identify in vivo phosphorylation sites, peptides were separated by reversed-phase 
Other Methods
Protein was measured by the Bradford method (26) using γ-globulin as a standard or by the reaction with ninhydrin after trichloroacetic acid precipitation and complete alkaline hydrolysis (27) using bovine serum albumine as a standard. SDS-polyacrylamide gel electrophoresis analysis in 10% or 7.5% (w/v) acrylamide was as described (28) . Kinetic constants were calculated by fitting data to a hyperbola by nonlinear least square regression using a computer program (Ultrafit, Biosoft, Cambridge, UK)
RESULTS
Purification of wild-type and mutant PKD preparations
Engineering of a N-terminal GST-tag in PKD allowed rapid purification of the protein by a one-step procedure. Cell lysates were directly mixed with Glutathione Sepharose 4B and GST-PKD preparations were eluted with reduced gluthatione. SDS-polyacrylamide gel electrophoresis analysis of the purified preparations of wild-type PKD (GST-PKD), PKD catalytic domain (GST-catPKD) and mutant proteins showed single 132000-Mr or 68000-Mr bands in agreement with the calculated masses. The purified proteins were stored in elution buffer at -80°C with no appreciable loss of activity over several months.
Characterization of purified wild-type and catalytic domain PKD
The catalytic domain of PKD had a 12-fold higher k cat than wild-type PKD (6 s ). The affinities for MgATP and syntide-2 were similar for the two recombinant enzymes, suggesting that the overall structure of the catalytic domain was maintained and that the GST tag had no influence on the kinetic properties of the enzyme (Table 1) . Likewise, addition of a N-terminal green fluorescent protein (GFP) tag in PKD has previously been shown to have no influence on PDBu induced translocation, basal catalytic activity, phorbol ester binding and kinase activation (29) . Moreover, in vitro incubation of GST-PKD with PS/PDBu micelles led to a 5-fold stimulation of PKD activity (not shown). A comparable stimulation was observed with untagged PKD (10, 23).
Incubation of HEK 293T cells with PDBu caused a 3-fold increase in k cat for GST-PKD with no effect on the affinities for MgATP and syntide-2 (Table 1) . By contrast, PDBu treatment had no effect on the activity of GST-catPKD. Therefore, deletion of the regulatory domain of PKD leads to a constitutively active kinase and these results suggest that the region for PKC-dependent activation is located outside the catalytic domain. These results support those obtained in experiments using partial deletions or point mutations in the regulatory domain of PKD (3, 6) .
Time course experiments of in vitro autophosphorylation showed that 32 Pincorporation into GST-PKD was maximal after 60 min and was maintained for up to 80 min (not shown). The initial rate of GST-PKD autophosphorylation was independent of enzyme concentration with an activity of 50 pmol/min/mg (not shown), indicating that autophosphorylation of GST-PKD occurs via an intramolecular event at a very slow rate.
Indeed, for Dictyostelium MLCK, which has a catalytic domain possessing 40% identity with the PKD kinase domain, autophosphorylation is also intramolecular, but with a 15-fold faster rate (30) . The stoichiometry of autophosphorylation of GST-PKD and GST-catPKD was 0.4 and 0.2 mole of phosphate incorporated per mol of enzyme, respectively, suggesting the existence of at least two autophosphorylation sites, one located in the catalytic domain, the other in the regulatory domain. The low incorporation of radioactive phosphate in vitro could reflect the fact that these sites were already largely phosphorylated in vivo (see below).
Ser-916 is an autophosphorylation site in vitro and in vivo and is involved in the downregulation of PKD activity after PDBu stimulation.
Purified GST-PKD was autophosphorylated in vitro by incubation with [γ-HPLC-ESI-MS/MS. Ser-916 was found to be phosphorylated in both conditions, indicating that Ser-916 is phosphorylated in vivo (Table 2) . Ser-916 was also found to be autophosphorylated in GST-catPKD, indicating that autophosphorylation of Ser-916 does not depend on the presence of the regulatory domain. Some minor radioactive HPLC peaks contained phosphopeptides generated by missed cleavages during proteolysis (P3 and P4 in Table 2 ) .
To study the role of Ser-916 autophosphorylation, this residue was mutated to alanine (S916A) or glutamate (S916E) and the kinetic properties of PKD were studied. The two mutants had similar kinetic parameters compared with wild-type GST-PKD, with no drastic changes in k cat or K m (Table 1) . Moreover, the S916A and S916E mutants could be activated in cells treated with PDBu to the same extent as wild-type GST-PKD (Table 1) . Mutation of Ser-916 to glutamate did not overcome the need for PKC-activity in the PDBu-mediated PKD activation (see below and Fig.6 ). Therefore, autophosphorylation of Ser-916 is not required either for activity or for in vivo activation by PDBu.
Other roles for phosphorylation sites in the carboxyl terminus in PKCs have been proposed. For example, C-terminal phosphorylation sites may increase protein stability or increase the resistance to dephosphorylation by protein phosphatases (32) . C-terminal phosphorylations have also been reported to affect protein subcellular partitioning, sensitivity to proteolysis or affinity for substrates, phosphatidylserine or Ca 2+ (33, 9) . Experiments were therefore undertaken to see whether phosphorylation at Ser-916 in GST-PKD could cause similar changes. For the S916E and S916A mutants, the PS/PDBu dependence of GST-PKD substrate phosphorylation was measured in the presence of mixed micelles containing Triton X-100 (34) . None of the mutations significantly affected the PS/PDBu dependence of the GST-PKD activity (not shown). We then tested the sensitivity of PKD towards proteolysis by trypsin. This technique has been used to study conformational changes in PKC, for example those induced by membrane binding (35) . Incubation of the in vivo PDBu-stimulated wildtype and S916E preparations with trypsin (0.02 units ml trypsin. By contrast, the S916A mutant was more resistant to proteolysis requiring higher concentrations of trypsin to obtain a similar pattern of proteolysis and intact enzyme was still apparent after incubation with 0.2 units ml -1 trypsin (Fig. 2) . We also investigated the sensitivity of the in vivo PDBu-stimulated wild-type and Ser-916 mutants towards dephosphorylation by alkaline phosphatase. Following in vitro autophosphorylation with [γ-32 P] MgATP and incubation with alkaline phosphatase, the wild-type and S916E preparations showed a time-dependent decrease in their extent of phosphorylation, whereas the S916A mutant was resistant to dephosphorylation (Fig. 3) . Finally, we investigated whether Ser-916 mutation could affect any in vivo properties of PKD, by examining the time dependent downregulation of PKD activity after PDBu stimulation. For this experiment untagged PKD constructs were cloned in pcDNA 3 vector and transiently transfected in HEK-293T cells.
After PDBu treatment, cells were washed and incubated for another 6 hours in DMEM medium without PDBu. PKD activity was measured after immunoprecipitation at different time points. The wild-type and S916E mutant showed a time-dependent decrease in activity reaching 56 or 64 % of initial activity respectively, after six hours (Fig.4) . The slow downregulation of the PKD activity seen after phorbol ester treatment confirms previous studies (36) . In contrast, PKD activity of the S916A increased during the first hour of incubation and decreased thereafter at a similar rate compared to the wild-type reaching 85% of initial activity after 6 hours (Fig.4) . We also tested whether this decrease in activity was reversible. After 6 hours of downregulation, cells were restimulated with PDBu without changing the medium. The PKD activity measured after the second PDBu stimulation was similar to the initial activity (after the first PDBu treatment), indicating that downregulation of PKD activity occurs via a reversible mechanism, probably reflecting reversible dephosphorylation of the enzyme (Fig.4) .
Identification of Ser-203 as a second in vitro and in vivo autophosphorylation site
The S916A and S916E mutants still autophosphorylate, suggesting the existence of other autophosphorylation sites, which were not detected after chymotryptic cleavage.
Therefore, autophosphorylated GST-PKD was digested with trypsin instead of chymotrypsin.
One major radioactive peak was isolated by HPLC and analyzed by nanospray ESI-MS/MS. This peak did not contain a peptide corresponding to the predicted short sequence containing Table 2 ). Fragmentation of the ions losing H 3 PO 4 confirmed that Ser-203 is phosphorylated in vivo (Fig 5) .
Identification of Ser-255 as an in vivo transphosphorylation site in PKD
HEK-293T cells, transiently expressing GST-PKD, were labeled with [ (Table 1) . Thus, mutation of Ser-255 into glutamate certainly did not induce a constitutively active form of PKD. However, PDBu treatment led to a greater degree of activation of the S255E mutant than the wild-type (11-versus 3-fold) . Surprisingly, mutation of Ser-255 to alanine did not abolish PDBu-induced activation, indicating that this site is not essential for PKD activation. To test whether this site might be phosphorylated downstream of a PKC-dependent signaling pathway, we studied the PDBu-induced activation of the S225E and S255A mutants in the presence and absence of Gö 6850. This PKC inhibitor prevents the activation of PKD in response to phorbol ester or mitogens (11, 15, 21) . Treatment of HEK 293T cells with Gö 6850 significantly decreased the PDBu-induced PKD activation of wildtype and S255A GST-PKD, but had no effect on the activation of the S255E mutant (Fig.6 ), indicating that this site is indeed phosphorylated by a PKC-dependent pathway upon stimulation with phorbol ester.
In vivo activation of full-length PKD by phorbol ester does not encompass phosphorylation of the activation loop Ser-744 and Ser-748
Ser-744 and Ser-748 in the activation loop of PKD have been proposed to become phosphorylated in intact cells in response to PDBu stimulation (23) . The authors used a combination of mutational analysis and two-dimensional peptide mapping to demonstrate the potential role of these two residues in the activation of PKD. However, the two phosphorylation sites were not unambiguously identified and a detailed kinetic study of the serine mutants was not performed. We did not find any radioactive peptides containing phosphorylated Ser-744 or Ser-748 in [ phosphorylated. This indicates that these two sites are not phosphorylated in full-length PKD, either in PDBu-stimulated or unstimulated cells.
We also searched for Ser-744 and Ser-748 phosphorylation in GST-catPKD.
Following in vitro autophosphorylation with [γ-32 P] MgATP, GST-catPKD was digested with chymotrypsin and peptides were separated by HPLC. Radioactive peaks were analyzed by nanospray ESI-MS/MS. In addition to the previously identified phosphorylated Ser-916, we were able to identify and sequence another phosphopeptide in which Ser-748 was phosphorylated (P2 in Table 2 ), indicating that this is an in vitro autophosphorylation site in the expressed catalytic domain. GST-catPKD was also analysed by on-line capillary HPLC-
ESI-MS/MS directly following purification from unstimulated cells. Ser-916 and Ser-748
were phosphorylated and we also identified phosphorylated Ser-744 (P8 in Table 2 ). This We also decided to investigate by site-directed mutagenesis the role of Ser-744 and Ser-748 in PKD activation by PDBu. The two serine residues were mutated to Glu or Ala in the full-length GST-PKD to generate four single points mutants (S744A, S744E, S748A and S748E). The mutants were then expressed in HEK 293T cells and purified as described above.
We studied the effects of the mutations on kinetic parameters ( Table 1) . Mutation of Ser-744 or Ser-748 to Ala drastically decreased the k cat by 22-or 8-fold, respectively, and increased the K m for syntide-2. The S744E mutant also displayed a lower k cat (4-fold) and there was a slight decrease in affinity for MgATP (2-fold). Mutation of Ser-748 to glutamate had no effect on the kinetic properties of PKD. Interestingly, all mutants could be activated in cells treated with PDBu. The S744A and S748A mutants were activated to the same extent as the wild-type (3 to 5-fold), whereas the S744E and S748E mutants displayed a 24-or 8-fold activation, respectively. Moreover, the S744E and S748E mutants were sensitive to Gö 6850 induced inhibition of PDBu-mediated PKD activation (Fig.6) . These results indicate that neither of the activation loop serines is involved in PDBu-induced activation, but that they may be involved 
Activation of PKD by proteolysis
PKC was originally described as a protein kinase which could be activated by limited proteolysis (38) . However, it is now generally accepted that a reversible activation of PKC, rather than irreversible proteolytic activation, is the major means of regulation for this family of kinases (39) . Nevertheless, an increasing number of kinases having a large regulatory domain (PAK, MEKK-1, PKCδ, PRK1) are activated by proteolysis (40, 41, 42, 43) . We tested whether PKD could be activated by proteolysis. Purified GST-PKD was incubated with 0.02 units ml -1 of trypsin and a time-course of PKD activation was studied (Fig.7) . Partial proteolysis resulted in the appearance of three major bands analyzed by SDS-PAGE with Mrs of 90000, 42000 and 26000 (Fig.7) , and resulted in an increase in the PKD activity (4 to 14-fold depending on the PKD/Trypsin molar ratio). In vivo treatment with PDBu prior to proteolysis had no effect on this proteolytic activation, suggesting that the trypsin cleavage sites do not only become exposed after phorbol ester stimulation (Fig.7) .
DISCUSSION
In this study we identified five phosphorylation sites in PKD, shown schematically in Ser-916 at the C-terminal end was found to be autophosphorylated in vitro and in vivo both in GST-PKD and in GST-catPKD (Fig 1 and Table 2 ). Interestingly, Ser-916 is not in a carboxy-terminal phosphorylation site consensus sequence FXXF(S/T)(Y/F) identified in other kinases (PKB, cPKCs, nPKCs and p70 S6K ) (47) . Using an anti phospho-Ser-916 antibody, it was shown that phosphorylation of Ser-916 correlated with PKD activity and was induced by phorbol ester or by antigen receptor triggering in lymphocytes (24) . Replacement of Ser-916 by alanine or glutamate demonstrated that autophosphorylation of Ser-916 is not required for activity or for in vivo activation by phorbol ester (Table 1) . Likewise in PKCβ II, where two autophosphorylation sites are located at the carboxyl terminus, one site (Ser-660) does not control the kinase activity but rather plays a structural role, in both the active site and the regulatory region, by increasing the affinity for substrates, phosphatidylserine and Ca 2+ (9, 33) . The S916A mutant showed a reduced sensitivity to proteolysis (Fig. 2) and to dephosphorylation by alkaline phosphatase (Fig 3) , which indicates that the Ser-916 to alanine mutant might have a more closed conformation, and that a C-terminal negative charge would favor a more open structure. Moreover, the Ser-916A mutant exhibited a delayed timedependent downregulation of its activity after phorbol ester stimulation (Fig. 4) . We also showed that the downregulation of PKD activity is a reversible process, probably under the control of a protein phosphatase (Fig. 4) . This is in agreement with our previous report showing that the activation of PKD can be fully reversed in vitro by protein phosphatases PP1 c and PP2A c (15) . There exist several examples of C-terminal kinase phosphorylation /dephosphorylation as a regulatory mechanism for kinase activity downregulation. For PKBα, downregulation of the kinase activity occurs via dephosphorylation of the two major regulatory phosphorylation sites (Thr-308 in the activation loop and Ser-473 at the C-terminal end). It is known that their mutation to aspartate leads to a constitutively active enzyme that cannot be downregulated (48) . As a variation on this theme, IKKβ also contains C-terminal autophosphorylation sites involved in the downregulation of its kinase activity (49) . However, replacement of these serines with alanine in IKKβ results in a mutant that remains active four times longer than the wild-type enzyme. Likewise, mutation of S916 to alanine in PKD instigates a slower downregulation of the kinase activity, while a negative charge at this position induced by phosphorylation or mutagenesis seems to favor the process (Fig. 4) , possibly by inducing a conformational change. This could render other phosphorylation sites more accessible to protein phosphatases which are involved in the reversal of kinase activation. It should be mentioned that the downregulation of PKD activity was postponed but not abolished in the S916A mutant, indicating that additional mechanisms are involved.
14-3-3τ proteins have been proposed to associate with PKCµ and to negatively regulate PKCµ kinase activity (50) . Mutational analysis suggested that this association involved two serine pairs (serines 205/208 and 219/223 in PKCµ) and both these pairs of serine residues were proposed to be autophosphorylation sites of PKCµ. However, in these studies, only combinations of double mutants were tested, which cannot pin-point the individual residues required for interaction with 14-3-3τ. Moreover the phosphorylated serine residue(s) were not positively identified. These two serine pairs are conserved in PKD and correspond to serines 203/206 and 217/221. Here we identified Ser-203 as an in vitro and in vivo autophosphorylation site in PKD. Ser-206 was detected as being non-phosphorylated (Table 2) . We have no evidence that a serine residue in the second pair is phosphorylated.
Moreover, we could identify and sequence peptides containing Ser-217 and Ser-221 in their non-phosphorylated states in autophosphorylated PKD.
We identified Ser-255 as a PDBu-induced transphosphorylation site in 32 P-labeled cells, downstream of a PKC-dependent pathway (Table 2) . Although the S255E mutant is not constitutively active, its activation by phorbol ester no longer requires PKC activity (Fig. 6) .
The demonstration that of all the mutants tested, only the S255E mutant can still be activated Our results demonstrate that Ser-744 and Ser-748 are not phosphorylated in full-length GST-PKD in response to phorbol ester stimulation (Table 2) . However, these two sites are autophosphorylated in vivo in GST-catPKD, which probably explains why GST-catPKD is highly active and cannot be further stimulated by the PDBu/PKC pathway (Table 1) . PKD does not belong to the family of RD kinases, which are defined as kinases where the conserved catalytic aspartate is preceded by an arginine residue. Most RD kinases are regulated by phosphorylation in the activation loop (8) . In the 3-D structures of several RD kinases, the arginine residue in the "RD motif" interacts with the phospho-amino-acid in the activation loop (e.g. cAPK, MAPK, CDK2) or with a corresponding acidic residue (e.g. PhK)
to promote the correct positioning of the catalytic site residues (7). Non-RD kinases, like PKD, are proposed not to be regulated by phosphorylation in the activation loop (8) . There is an interesting double substitution in twitchin, the only non-RD kinase of known structure, with the ion-pair seen in RD kinases being replaced by two uncharged residues (valine and leucine) (52) . This probably explains why this kinase is not regulated by phosphorylation in One might envisage an alternative pathway for PKD activation where a protease driven mechanism would be involved. Interestingly, one study has shown that stable PKCµ transfectants exhibit a reduced sensitivity to tumor-necrosis-factor (TNF)-induced apoptosis (16) . The authors reported that PKCµ is stimulated by TNF and promotes the activation of NF-κB dependent genes, counteracting apoptotic signals. More recently, it was shown that treatment of cells with various apoptosis-inducing agents caused a caspase-3 mediated proteolytic cleavage of PKCµ, between the regulatory and catalytic domain (53) . The caspase-
In conclusion, phosphorylation of PKD at particular sites may be an intricate mechanism for the selective control of its biological functions. More work is in progress on the hierarchy of the observed phosphorylations and their potential role for the association of PKD with other proteins. Finally, further studies will be needed to investigate whether other activating signalling pathways such as Gβγ subunits or caspase-mediated proteolysis lead to differential phosphorylation of PKD. (17, 22, 50, 54, 55) .
